Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866081 | 1.00 | LMNA (0.53) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13880679 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2030380 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL21585062 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2611574 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL2030383 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL13258657 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL18214117 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL8165992 | 0.87 | LMNA (0.55) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL24922883 | 0.85 | LMNA (0.34) | LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6312953-B1 | MODIFIED OLIGONUCLEOTIDE COMPLEMENTARY TO A TARGET SEQUENCE AND HAVING AT LEAST TWO CROSSLINKING AGENTS COVALENTLY ATTATCHED; GENE EXPRESSION INHIBITION; DNA SEQUENCING; GENETIC MAPPING | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0842186-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997012896-A1 | SELECTIVE BINDING COMPLEMENTARY OLIGONUCLEOTIDES | EPOCH PHARMACEUTICALS, INC. (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996040711-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1994017092-A1 | BIFUNCTIONAL CROSSLINKING OLIGONUCLEOTIDES ADAPTED FOR LINKING TO A DESIRED GENE SEQUENCE OF INVADING ORGANISM OR CELL | MICROPROBE CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |